What is the Sonobird clinical trial?
Sonobird is an ongoing clinical trial currently recruiting patients in Europe and the USA. It evaluates the efficacy of the combined use of an implantable ultrasound device, the SonoCloud-9, to open the blood-brain barrier (BBB), and a chemotherapy, carboplatin, for the treatment of recurrent glioblastoma.
Why open the BBB with SonoCloud-9?
The BBB is located at the blood vessel walls. It protects the brain from any toxic or inflammatory molecules, but it also prevents most drugs injected in the bloodstream from getting into brain tissue where the tumor is located. The development of effective treatments against brain disease is thus limited due to the presence of the BBB.
The SonoCloud-9 (SC9) is a medical device based on ultrasound technology. It is specially developed to transiently open the blood-brain barrier (BBB) in the area of and surrounding the tumor where most therapeutic agents cannot readily penetrate. The device is able to increase the concentration of chemotherapy in the brain tissue where the tumor is located. It uses an implant, a transdermal needle, a generator and microbubbles. It has previously been evaluated in recurrent glioblastoma patients in Phase 1/2 trials.
Further information about the SC9 device can be found on the Our SonoCloud-9 Device page.
Video for illustration purposes only. To access the video, please accept the cookies required for the site to function properly.
What are the objectives of the SONOBIRD trial ?
The objective of the Sonobird trial is to show that the association of carboplatin with the SonoCloud-9 will increase efficacy of the chemotherapy in patients with recurrent glioblastoma. The trial will evaluate the effectiveness of the treatment by SonoCloud-9 and carboplatin to prolong life in comparison with standard of care treatment (lomustine or temozolomide). The safety of the treatment by SonoCloud-9 and carboplatin and its effectiveness on tumor growth will also be assessed in comparison with standard of care by recording the patients’ disease status for the duration of the trial.
To be able to compare the effectiveness and safety of each treatment, patients taking part in this research will be randomized into one of two groups. Participants in the experimental group will be given SonoCloud-9 and carboplatin while participants in the standard of care group will be given the standard of care (lomustine or temozolomide).
How does the Sonobird trial work?
Click here to find out more about the Sonobird clinical trial.
Who can take part in this clinical trial against glioblastoma?
For more information, please refer to the page on eligibility criteria.
